Purpose of reviewBased on the recent data of the DA VINCI study, it is clear that, besides utilization of statins, there is a need to increase non-statin lipid lowering approaches to reduce the cardiovascular burden in patients at highest risk.Recent findingsFor hypercholesterolemia, the small synthetic molecule bempedoic acid has the added benefit of selective liver activation, whereas inclisiran, a hepatic inhibitor of the PCSK9 synthesis, has comparable effects with PCSK9 monoclonal antibodies. For hypertriglyceridemia, cardiovascular benefit has been achieved by the use of icosapent ethyl, whereas results with pemafibrate, a selective agonist of PPAR-alpha, are eagerly awaited. In the era of RNA-based therapies, new options are offered to dramatically reduce levels of lipoprotein(a) (APO(a)L-RX) and of triglycerides (ANGPTL3L(RX) and APOCIII-L-Rx).SummaryDespite the demonstrated benefits of statins, a large number of patients still remain at significant risk because of inadequate LDL-C reduction or elevated blood triglyceride-rich lipoproteins or lipoprotein(a). The area of lipid modulating agents is still ripe with ideas and major novelties are to be awaited in the next few years.

Lipid Lowering Drugs: Present Status and Future Developments / M. Ruscica, N. Ferri, R.D. Santos, C.R. Sirtori, A. Corsini. - In: CURRENT ATHEROSCLEROSIS REPORTS. - ISSN 1523-3804. - 23:5(2021 May), pp. 17.1-17.13. [10.1007/s11883-021-00918-3]

Lipid Lowering Drugs: Present Status and Future Developments

M. Ruscica
Primo
Writing – Review & Editing
;
C.R. Sirtori;A. Corsini
Writing – Review & Editing
2021

Abstract

Purpose of reviewBased on the recent data of the DA VINCI study, it is clear that, besides utilization of statins, there is a need to increase non-statin lipid lowering approaches to reduce the cardiovascular burden in patients at highest risk.Recent findingsFor hypercholesterolemia, the small synthetic molecule bempedoic acid has the added benefit of selective liver activation, whereas inclisiran, a hepatic inhibitor of the PCSK9 synthesis, has comparable effects with PCSK9 monoclonal antibodies. For hypertriglyceridemia, cardiovascular benefit has been achieved by the use of icosapent ethyl, whereas results with pemafibrate, a selective agonist of PPAR-alpha, are eagerly awaited. In the era of RNA-based therapies, new options are offered to dramatically reduce levels of lipoprotein(a) (APO(a)L-RX) and of triglycerides (ANGPTL3L(RX) and APOCIII-L-Rx).SummaryDespite the demonstrated benefits of statins, a large number of patients still remain at significant risk because of inadequate LDL-C reduction or elevated blood triglyceride-rich lipoproteins or lipoprotein(a). The area of lipid modulating agents is still ripe with ideas and major novelties are to be awaited in the next few years.
APOCIII-L-Rx; ANGPTL3L(RX); Inclisiran; Lipoprotein(a); Proprotein convertase subtilisin; kexin type 9;
Settore BIO/14 - Farmacologia
Settore MED/04 - Patologia Generale
10-mar-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
Massimiliano Ruscica.pdf

accesso aperto

Descrizione: Online first
Tipologia: Publisher's version/PDF
Dimensione 677.96 kB
Formato Adobe PDF
677.96 kB Adobe PDF Visualizza/Apri
Ruscica2021_Article_LipidLoweringDrugsPresentStatu.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 674.01 kB
Formato Adobe PDF
674.01 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/822239
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 23
social impact